Search
Monopar Therapeutics Inc
MNPRAdd to Watchlist
110.450USD
+0.580+0.53%
Close 07-27 16:00（ET）Quotes delayed by 15 min
739.91MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Monopar Therapeutics Inc is 8.31, ranking 136 out of 386 in the Biotechnology & Medical Research industry. The average price target is 109.00, with a high of 130.00 and a low of 93.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
116.846
Target Price
+6.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Monopar Therapeutics Inc
MNPR
13
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Monopar Therapeutics Inc's price target?
Analysts forecast that Monopar Therapeutics Inc's price target is USD 109.00, with the highest forecast at USD 130.00 and the lowest forecast at USD 93.00.
How have Monopar Therapeutics IncMNPR's recent earnings per share performed?
The market expectation was USD -0.46, while Monopar Therapeutics IncMNPR's earnings per share (EPS) for the previous quarter was USD -0.61. EPS for the next quarter is expected at USD -0.62.
What is the analyst rating for Monopar Therapeutics Inc?
Based on the ratings of Monopar Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.